Methods: This project surveyed 33 participants who participated in 3 different clinical trials for peanut. Questionnaires were distributed about study participation, desensitization method and impact on daily life.
Results: All participants responded and were happy they participated. 29 subjects introduced peanut into their diet. However, 16 reported dosing interfered with daily life.
Quantity of peanut consumption varied. 89% of O+OIT consumed at least 300 mg compared to 56% with OIT and 53% with EPIT. 11% of O+OIT patients are completely avoiding compared to EPIT (20%) and OIT (22%). Dosing frequency varied from once per month to daily.
Only six participants liked the taste and were from the EPIT cohort. One patient in each OIT and O+OIT groups was interested in eating more compared to nine (82%) EPIT.
Since completion, four experienced allergic reactions requiring epinephrine due to dosing (O+OIT: 3; EPIT: 1). Two participants in both the OIT and O+OIT currently complain of increased gastrointestinal symptoms.
Conclusions: Overall participants had success, yet incorporating continued ingestion proves challenging and optimum dosing still needs to be determined. The O+OIT group reached the highest doses, but had the greatest frequency of reactions. The EPIT group appears to like peanut suggesting a possible different mechanism of immunotherapy.